Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202974 | 0.81 | — | — | |
| SCHEMBL18654167 | 0.81 | LMNA (0.41) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL9581435 | 0.79 | — | — | |
| SCHEMBL6436283 | 0.77 | THRB (0.39) | THRBLMNAL3MBTL1TDP1 | |
| SCHEMBL13042255 | 0.75 | — | — | |
| SCHEMBL29419443 | 0.75 | THRB (0.38) | THRBLMNAL3MBTL1TDP1 | |
| SCHEMBL2738533 | 0.72 | — | — | |
| SCHEMBL25422268 | 0.70 | PTPN1 (0.34) | AKR1B1LMNA | |
| SCHEMBL4451315 | 0.70 | AKR1B1 (0.32) | AKR1B1 | |
| SCHEMBL21633313 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168422-A1 | METHODS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF HEXAHYDROFURO [2,3-B]FURAN-3-OL | CLINTON HEALTH ACCESS INITIATIVE, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168422-A1 | METHODS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF HEXAHYDROFURO [2,3-B]FURAN-3-OL | CLINTON HEALTH ACCESS INITIATIVE, INC. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168422-A1 | METHODS AND INTERMEDIATES USEFUL IN THE SYNTHESIS OF HEXAHYDROFURO [2,3-B]FURAN-3-OL | FDPS, DHFR, AKR7A2 | AKR1B1 149/4885THRB 3819/4885LMNA 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.